Evidence map›Paper›PMID 42171670›Full record

ReviewJournal of endocrinological investigation2026

The impact of mineralocorticoid receptor antagonists on fat mass and fat metabolism.

Baris Afsar, Rengin Elsurer Afsar, Geetha Maddukuri

Abstract readReview
In one paragraph

Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Baris AfsarSchool of Medicine, Department of Nephrology, Suleyman Demirel University, SuleymanDemirel University Hospital, Cunur, 32260, Isparta, Turkey. afsarbrs@yahoo.com.ORCID http://orcid.org/0000-0002-1369-3657
Rengin Elsurer AfsarSchool of Medicine, Department of Nephrology, Saint Louis University, SSM Health Saint Louis University Hospital, St Louis, MO, USA.
Geetha MaddukuriDivision of Nephrology and Hypertension, VA Saint Louis Health Care System, St Louis, MO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionObesity is a chronic, multifactorial condition which is a global health challenge. In general, obesity is defined by excessive fat accumulation and associated with the risk of numerous conditions, including type 2 diabetes mellitus (T2DM), cardiovascular disease, heart failure, and metabolic dysfunction-associated steatotic liver disease, and some types of cancer contributing to increased morbidity and mortality. Mineralocorticoid receptor antagonists (MRAs) are used for a long time for management of cardiovascular disease and non-steroidal MRAs also showed kidney protection. Apart from these, there is growing literature showing that MRAs effecting fat mass and fat metabolism. In this review, we summarised the effects of MRAs on fat mass and fat metabolism.

resultsIn general, studies showed that MRAs reduced fat mass in various organs which is associated decreased oxidative stress, inflammation, and insulin resistance. Importantly, MRAs increased adipose tissue browning and decrease white adipose tissue mass. Up to now, the studies showed no safety signals and these favorable effects are independent of blood pressure reduction. Discussion A part from hemodynamic effects, MRAs have beneficial impacts on fat mass and fat metabolism. Currently, the underlying mechanisms for these effects are not clear Conclusions: Preliminary studies have shown that MRAs have favorable impact on fat metabolism and fat mass. Studies needed to highlight underlying mechanisms..

Indexed as

Adipose TissueLipid MetabolismMineralocorticoid Receptor AntagonistsObesityAnimalsHumansMineralocorticoid Receptor AntagonistsEplerenoneFatFinerenoneMineralocorticoid receptor antagonistsObesitySpironolactone

Identifiers

PMID42171670
PMCPMC13498517

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.